Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002050788 | SCV002112467 | uncertain significance | Pancreatic adenocarcinoma | 2021-04-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with PALLD-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with histidine at codon 490 of the PALLD protein (p.Arg490His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine. |
Ambry Genetics | RCV004038795 | SCV002748574 | uncertain significance | not specified | 2024-01-01 | criteria provided, single submitter | clinical testing | The p.R977H variant (also known as c.2930G>A), located in coding exon 16 of the PALLD gene, results from a G to A substitution at nucleotide position 2930. The arginine at codon 977 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |